Compare TLIH & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLIH | TPST |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | Singapore | United States |
| Employees | 70 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 15.6M |
| IPO Year | 2023 | 2012 |
| Metric | TLIH | TPST |
|---|---|---|
| Price | $5.77 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 1.8K | ★ 227.6K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.34 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.22 | $0.84 |
| 52 Week High | $5.96 | $12.22 |
| Indicator | TLIH | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 61.28 | 54.36 |
| Support Level | $5.11 | $1.02 |
| Resistance Level | $5.89 | $1.26 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 97.26 | 39.80 |
Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental, and provision of engineering consultancy services to port, construction, civil engineering, and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment, and port machinery. The company operates in Singapore and Other international countries.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.